Bio Sequence

Mapping the Evolution of the Competitive Landscape of Mirvetuximab Soravtansine

26 October 2023
3 min read

A significant milestone was recently achieved in the evolution of the ovarian cancer therapeutic landscape, with China's National Medical Products Administration (NMPA) issuing a Notice of Acceptance to Huadong Medicine Co., Ltd. This pharmaceutical giant and its collaborator, ImmunoGen, Inc., based in America, received acceptance for their Market Application for the groundbreaking drug, Mirvetuximab Soravtansine Injection.

Pertaining to the Sotuximab Monotherapy Injection

The key highlight of this injection is its first-in-class characterization, being an ADC drug, that is a joint venture of Huadong Medicine and ImmunoGen. The unique component the drug targets is the Folate Receptor α (FRα), which is a cell surface protein, responsible for the aggressive multiplication of ovarian cancer cells. The sophisticated construction of this drug incorporates FRα binding antibodies, cleavable linkers and the maytansinoid DM4 substance.

Patenting Landscape of Mirvetuximab Soravtansine: Top 10 Assignees

Source, Patsnap Bio

Evolution of the Layout of Top 10 Patent Assignees over the years, the Competitive landscape over time

In mapping the evolutionary trajectory of the patenting landscape pertaining to Mirvetuximab Soravtansine, it is critical to analyze the strategic approach of the top 10 assignees. There is also a dynamic shift in the competition blueprint that is dictated by the progression of time.

Source, Patsnap Bio

Requisite Steps for Accessing Comprehensive Sequence Patent Details about Mirvetuximab Soravtansine

Interested parties could utilize the Patsnap Bio Sequence Database, which is easily accessible by creating a free account. On the home page, you can either enter the molecular sequence of Mirvetuximab Soravtansine into the "Common Search" bar or simply key in the drug's name in the "Drug/Gene Index." A single search effort would provide an array of information, such as: sequence specifics, related literature, patent particulars, relevant additional data, and a visual display of the drug’s competitive patent landscape.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 应用程序

描述已自动生成

图形用户界面, 应用程序

描述已自动生成

For an enhanced search experience, the interface provides a robust filtering mechanism, streamlining your desired details. Delving into each data entry further provides access to a rich collection of related data, along with efficient, user-friendly features to augment your research endeavors.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

It is important to note that Patsnap Bio is the most extensive sequence search platform for the Patsnap database. It incorporates AI with human-curated data for comprehensive handling of protein and nucleotide sequence data plucked from global patents, biological periodicals, and public repositories. Essential biological sequences are manually annotated, illuminating structural modifications to provide the most accurate sequence data and boost sequence retrieval efficiency.

Free registration is available for the Bio biological sequence database: https://bio.patsnap.com. Act now to expedite your sequence search tasks.

Benzydamine Hydrochloride Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
Drug Insights
4 min read
Benzydamine Hydrochloride Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
30 October 2023
This article summarized the latest R&D progress of Benzydamine Hydrochloride, the Mechanism of Action for Benzydamine Hydrochloride, and the drug target R&D trends for Benzydamine Hydrochloride.
Read →
 Unleashing the Power of Benazepril Hydrochloride: A Comprehensive Review on R&D Breakthroughs
Drug Insights
4 min read
Unleashing the Power of Benazepril Hydrochloride: A Comprehensive Review on R&D Breakthroughs
30 October 2023
This article summarized the latest R&D progress of Benazepril Hydrochloride, the Mechanism of Action for Benazepril Hydrochloride, and the drug target R&D trends for Benazepril Hydrochloride.
Read →
A Comprehensive Review of Belantamab mafodotin's R&D Innovations and Drug Target Mechanism
Drug Insights
4 min read
A Comprehensive Review of Belantamab mafodotin's R&D Innovations and Drug Target Mechanism
30 October 2023
This article summarized the latest R&D progress of Belantamab mafodotin, the Mechanism of Action for Belantamab mafodotin, and the drug target R&D trends for Belantamab mafodotin.
Read →
Pharmaceutical Insights: Baloxavir Marboxil's R&D Progress and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Pharmaceutical Insights: Baloxavir Marboxil's R&D Progress and its Mechanism of Action on Drug Target
30 October 2023
This article summarized the latest R&D progress of Baloxavir Marboxil, the Mechanism of Action for Baloxavir Marboxil, and the drug target R&D trends for Baloxavir Marboxil.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.